Introduction
Risk categorisation in childhood acute lymphoblastic leukaemia (ALL) has become increasingly complex and now combines clinical factors such as WBC, age, gender and speed of response with identification of cytogenetic and molecular genetic abnormalities, 1, 2 and most recently the monitoring of minimal residual disease by molecular methods. [3] [4] [5] The aim of such strategies is to identify patients at high risk of treatment failure who may benefit from more intensive treatment and those in whom treatment may, perhaps, be safely reduced to avoid possible long-term morbidity. 6 Although there are some sub-groups of patients with ALL who have a much better prospect of cure than others, [7] [8] [9] there is also good evidence that it is these very patients who have benefited most from intensified treatment protocols. 10, 11 In keeping with results of other studies conducted in the last 15 years, 12, 13 14 This was obtained with two short 5-day intensification blocks more closely resembling acute myeloid leukaemia-type treatment regimens, rather than the extended 8 week intensification introduced by the German Berlin-Frankfurt-Munster (BFM) group, 13 the latter approach having been investigated in randomised trials by the American CCG. 12 The successor UK trials, MRC UKALL XI and ALL97, tested in a randomised fashion whether a third block of extended intensification at 35 weeks would benefit patients when added to the UKALL X regimen including the two short blocks.
Patients and methods

Patients
1781 consecutive children with ALL were randomised to a third intensification block or not in two MRC studies, UKALL XI and ALL97, between March 1992 and July 1998. UKALL XI accrued 2090 patients from August 1990 to March 1997 but the third intensification randomisation was only introduced in March 1992. ALL97 continued accruing patients to this randomisation until June 1998, when results were revealed by an independent data monitoring committee after the fifth interim analysis and randomisation halted in order for all subsequent patients to receive the third block. This report contains follow-up of all randomised patients to October 1998.
Eligibility criteria for entry to the two studies were different. UKALL XI recruited all ALL patients aged 1-15 years inclusive, except mature B cell; whilst ALL97 randomised children aged 1-18 years considered to have standard risk ALL by the Oxford hazard score, 7 based on initial WBC, age and gender but excluded patients in whom cytogenetic or molecular genetic studies showed PhЈ-positive ALL, balanced translocations involving chromosome 11q23 or near-haploidy.
894 (50%) of the 1781 randomised patients were allocated three intensification blocks (third block arm) and 887 received only two intensification blocks (non-third block arm). Characteristics of third block and non-third block recipients are described in Table 1 which shows that the groups were matched for age, gender, white cell count (WCC) at presentation and other presenting features.
Treatment protocols
Details of the randomisation scheme and treatment schedules are shown in Figure 1 and Table 2 . All patients received a 4 week induction course followed by two 5-day intensification blocks at weeks 5 and 20 identical to the schedule associated with the best outcome in UKALL X.
14 They were then randomised to receive, or not, an 8 week third intensification block /l which has been reported separately, 15 and HD-MTX vs fractionated (24 Gy in
Figure 1
Flow chart of UKALLXI and ALL97 protocols.
Leukemia 15 fractions of 1.6 Gy each) cranial radiotherapy for those with presenting WCC у50 × 10 9 /l. The randomisation for high risk patients with respect to irradiation continues to accrue patients in MRC ALL97. In addition, MRC ALL97 continues to accrue patients to a randomised comparison of dexamethasone vs prednisolone during induction and continuing treatment, and mercaptopurine vs thioguanine during continuing treatment. Patients with presenting WCC Ͻ50 × 10 9 /l receive IT MTX alone as CNS-directed treatment in MRC ALL97. 15 Individual centres in the UK obtained approval from their local research ethics committees, and informed consent from parents and patients, before entering patients into these protocols.
Randomisation method and statistics
Randomisation was done centrally on computer for both trials, and minimisation 16 was used to balance within age, gender, WCC and CNS therapy allocated in UKALLXI, plus steroid and thiopurine allocated in ALL97. The planned sample size was 2500, for detection of a 5% difference with 80% power. No formal stopping rule was used, but the data monitoring committee was required to report the results to the steering committee if, in the light of results from an interim analysis and from any relevant randomised trials elsewhere, there was evidence beyond reasonable doubt that one treatment arm was clearly indicated or clearly contraindicated.
The main analyses used the logrank method 17 with death or any event (relapse or death) as the primary endpoints. Secondary endpoints were bone marrow relapse, relapse without bone marrow involvement and death in first remission. Analyses of these excluded the patients who died without achieving remission. Estimates of event rate ratios within subgroups were calculated using the one-step approximation to the odds ratio. 18 Cox regression analysis 19 was used to confirm the independence of variables by use of the SAS statistical package.
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Results
Study violations
Of the 1781 randomised children, one in the no third block arm was given non-protocol treatment prior to achievement of remission and died of GVHD following an allogeneic bone marrow transplant in first remission. This patient has been counted as a death in remission in the survival analyses. Additionally, two patients were found to have high risk features (one with MLL gene rearrangement and one with near haploidy) after they had been randomised and were subsequently treated on the concurrent Medical Research Council high-risk protocol, ALL-HR1. These patients are all included in the intention-to-treat analyses to avoid post hoc bias.
Treatment outcome
Five patients died during induction treatment (two third block and three non-third block). Fifty-four patients failed to achieve a complete remission (31 third block and 23 non-third block) after 28 days of induction treatment. Of these, 52 remitted after receiving the first intensification block alone or with additional courses as further induction therapy, while two died with resistant disease (see Table 3 ). These non-remitters at day 28 had a poor outcome with 5-year EFS of 35% (95% CI = 11-59%).
At a median follow-up of 4 years (range 5 months to 8 years 1 month), 5-year disease-free survival is significantly better for patients in the third block arm (68%, 95% CI = 64-72%) compared with the no third block arm (60%, 95% CI = 56-64%) (Figure 2 , OR 0.75, logrank 2P = 0.002). This difference was primarily due to fewer bone marrow relapses amongst patients who received three intensifications (third block 24% vs nonthird block 30% at 5 years, 2P = 0.02, Figure 3 ), although the incidence of extramedullary relapses was also non-significantly lower (Figure 4 , third block 9% vs non-third block 11% at 5 years, 2P = 0.3). The effect on event-free survival remained significant (2P = 0.003) if those with events before week 35, the time at which the third block was given, were excluded. Table 3 Causes of non-relapse deaths in the two arms 
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Overall survival was not significantly affected by the third block ( Figure 5 , third block 87% vs no third block 85% at 5 years, 2P = 0.2), since there was somewhat better salvage of no third block arm relapses with 58% survival 3 years postrelapse against 52% for those relapsing in the third block arm (not significant; 2P = 0.2).
There was no statistically significant difference in the effect of third intensification between subgroups by age, white blood count, immunophenotype or international risk groups (Figure 6 ). However, the number of patients with T cell disease was small so there is some uncertainty about the benefit or not for them, and there were only 48 patients in the risk group defined by age 10 years or more and white cell count 50 × 10 9 /l or above. Analyses within groups according to CNS-directed therapy allocation also gave very similar results for the effect of the third block in each group, but with only 16 events among the ALL97 patients due to the length of follow-up, it is not possible to split the analysis by steroid or thiopurine allocation.
Treatment toxicity
Twenty-two deaths occurred during first complete remission (CR). Of these patients, six were recipients of the third block and 16 were not. Inspection of the causes of non-relapse deaths (Table 3) reveals that the excess deaths in non-third block recipients were primarily due to infection and secondary leukaemia: only one death occurred during or shortly after the third block.
The third block was associated with moderate excess morbidity. Antibiotics were used in 53% of third block recipients but only four patients (0.6%) received amphotericin, and 58% of patients requiring antibodies received only 1 week or less. Although 75% of patients experienced some degree of neutropenia, it was severe (Ͻ0.1 × 10 9 /l) in only 15% and did not persist beyond 1 week in 80% of these patients. Sixty-eight percent of patients had neutropenia of less than 0.5 × 10 9 /l. Intravenous feeding was required in only 1.8% of patients, suggesting that mucositis was an insignificant problem in the vast majority. Gut toxicity occurred in only 20% of patients and was severe in 0.3%. Two-thirds of patients required blood product support but moderate to severe bleeding was reported in only 3% of patients. These treatment-related complications resulted in 25% of patients being unable to complete the full third block. Additionally, 51% had their treatment interrupted due to complications during the third block. Of these, 72%, 25% and 3% suffered one, two and three such interruptions respectively, resulting in a 1 to 7 week delay in completion of their treatment.
Prognostic factors
Cox regression analysis showed that age, gender, WCC, late remission and third block allocation were all of independent prognostic importance. The Oxford hazard score 14 (0.22 + log [WCC + 1] + 0.0043 × age 2 − 0.39 × sex; boy = 1, girl = 2) remained valid for defining a small group of very high risk patients (score Ͼ 0.8) in both the third block arm (5 year EFS = 41%, 95% CI = 28-55%) and the non-third block arm (5 year EFS = 39%, 95% CI = 25-53%), consisting of about 6% of those randomised.
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Figure 2
Event-free survival by randomised treatment.
Figure 3
Cumulative incidence of bone marrow relapse (isolated or combined) by randomised treatment, censoring at other relapse or death in remission. Seven patients who never achieved remission are excluded.
Discussion
The results of MRC UKALL XI and ALL97 presented here reinforce and extend the findings of UKALL X that intensification of treatment is of benefit to all children with ALL. This randomised comparison in a large group of children of all risk categories indicates that the addition of a third block of intensification therapy at 35 weeks improved 5 year event-free survival by about 8%. Patients of all risk categories had a superior outcome with three blocks of intensification therapy, with no suggestion of less benefit in lower risk patients. The extra intensification offered protection against marrow relapse, although extra-medullary disease was also marginally reduced in the third intensification group.
There have been a number of recent trials demonstrating the benefit of various intensified regimens in selected higher risk patients with ALL 21, 22 but two recent randomised trials have involved patients with standard risk ALL. The German BFM 86 included a randomisation to a further 4 week intensification of treatment at 12 months for standard risk patients with no improvement in event-free survival but only one quarter of eligible patients were randomised. 13 The CCG randomised over 1200 patients to receive double delayed intensification, intensified vincristine and prednisolone, or standard treatment at 9-10 months. Patients receiving double delayed intensification had a 7.5% improvement in EFS at 5 years. 23 It is uncertain whether it was the mere application of a further block of intensification which led to the improved outcome in UKALL XI and ALL97, or whether the design of the schedule has made an important contribution. The 8-week intensification regimen tested here was similar to the prolonged schedules originally devised by the German BFM group 24 and later modified by the American CCG 12 group of investigators. It is a departure from the short, but extremely myelosuppressive, 5 day blocks shown to be effective in UKALL X, not just in duration but also in containing a re-
Figure 4
Cumulative incidence of non-bone marrow relapse by randomised treatment censoring at any bone marrow relapse or death in remission. Seven patients who never achieved remission are excluded.
Figure 5
Overall survival by randomised treatment.
induction component and different drug combinations. In the absence of any randomised comparisons of the two types of schedule it is impossible to know if the more prolonged treatment is better. It is however possible that the more prolonged schedule provides increased dose intensity over a prolonged duration at a time when minimal residual disease levels may be starting to rise in a proportion of patients. 25 Although the toxicity of the third block was only moderate it precluded completion of the full 8 weeks in around 25% of patients. Remarkably, only one of 900 patients given the third block in multiple centres died from complications which could in any way be related to it directly. It is possible that the improvement in outcome with a third block would be even greater if the full block was administered to a higher proportion of patients which the moderate morbidity and low mortality should permit.
This report adds to the evidence that additional intensifiLeukemia cation has benefit for all currently defined risk group patients. 23, 24 Whether a group of patients can be defined with sufficiently low risk of relapse to warrant exclusion from protocols involving further intensification of treatment is unproven at present. The use of newer technologies to detect minimal residual disease has identified patients in whom persistent disease after early treatment predicts a high risk of relapse. 25 However, it is not known whether patients with no detectable minimal residual disease after some months can be deemed 'cured' and may safely curtail treatment. Pending such information it is perhaps more appropriate to explore improvements in treatment for standard risk patients by alterations in therapy which combine a possibility of improved survival with low risk of late morbidity. Such investigations of steroid treatment and thiopurines are in progress in ALL 97 and in randomised trials performed by other collaborative groups.
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Figure 6
Effect of third block on event rates within subgroups by gender, age, white blood count and immunophenotype. The ratio of the annual event rates with and without the third block in each subgroup is represented by a square, with a horizontal line indicating the 95% confidence interval. The overall result is represented by the diamond, whose width shows the 95% confidence interval.
